Skip to main navigation Skip to search Skip to main content

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma; Daniel V. T. Catenacci, MD, and colleagues present findings from a study of cir

Press/Media

Period27 Apr 2023

Media coverage

1

Media coverage